FOOD AND DRUG ADMINISTRATION (FDA) Center for Biologics Evaluation and Research (CBER)

Friday, March 4, 2016

142nd Meeting of the Vaccines and Related Biological Products
Advisory Committee
FDA White Oak Campus, Building 31, Great Room (Room 1503)
Silver Spring, MD 20993

Live Webcast: https://collaboration.fda.gov/vrbpac030416/.

AGENDA

AGENDA	
Time	Presentation/Presenter
8: 30 A.M.	Call to Order and Opening Remarks
	Introduction of Committee
	Ruth Lynfield, M.D.
	Acting Chair, VRBPAC
	Conflict of Interest Statement
	Sujata Vijh, Ph.D.
	Designated Federal Officer,
	VRBPAC, FDA
	Topic: Strain Selection for the Influenza Virus Vaccines for
	the 2016-2017 Influenza Season
8:45a.m.	Introduction
	Anissa Cheung, M.Sc.
	Regulatory Coordinator
	Division of Viral Products
	Office of Vaccines Research and Review
	CBER/FDA
8:55 a.m.	U.S. Surveillance
	Lisa Grohskopf, M. D., M. P. H.
	CAPT. USPHS
	Associate Chief for Policy & Liaison Activities,
	Epidemiology & Prevention Branch, Influenza Division
	Centers for Disease Control and Prevention
9:20 a.m.	World Surveillance/ Virus Characterization
	Jacqueline Katz, Ph.D.
	Deputy Director (Acting),
	Influenza Division Director,
	WHO Collaborating Center for Surveillance, Epidemiology and
	Control of Influenza,
	Center for Immunization & Influenza,
	Center for Immunization & Respiratory Diseases
12.22	Centers for Disease Control and Prevention
10:20 a.m.	BREAK

Time	Presentation/Presenter
10:35 a.m.	DoD Vaccine Effectiveness Report
	Michael Cooper, Ph.D. CAPT, PHS
	Leader, Respiratory Pillar Activities
	Division of Global Emerging Infection Surveillance
	Armed Forces Health Surveillance Center
10:55 a.m.	Vaccine Responses
	Zhiping Ye, M.D., Ph.D.
	Senior Investigator
	Division of Viral Products
	Office of Vaccines Research and Review
	CBER/FDA
11:15 a.m.	Candidate Vaccine Strains & Potency Reagents
	Manju Joshi, Ph.D.
	Lead Biologist
	Division of Biological Standards & Quality
	Office of Compliance and Biologics Quality
	CBER/FDA
11:35 a.m.	Comments from Manufacturers
	Matthew Downham, Ph.D.
	Associate Director,
	Biopharmaceutical Development
	AstraZeneca/MedImmune
11:55 a.m.	LUNCH
12:50 p.m.	Open Public Hearing
1:50 p.m.	Committee Discussion, Voting and Recommendations
3:00 p.m.	Adjournment